We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.96%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$783M
AUM Growth
+$86.9M
Cap. Flow
+$43.3M
Cap. Flow %
5.53%
Top 10 Hldgs %
30.88%
Holding
120
New
12
Increased
45
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$13.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.8M
3
GKOS icon
Glaukos
GKOS
+$11.5M
4
AGN
Allergan plc
AGN
+$11.2M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$14.2M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$13.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$11.6M
4
NVCR icon
NovoCure
NVCR
+$10.8M
5
BIIB icon
Biogen
BIIB
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Financials 1.39%
3 Technology 0.15%
4 Energy 0.13%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
26
Elevance Health
ELV
$84.9B
$10.4M 1.33%
55,000
+28,532
+108% +$5.43M
CI icon
27
Cigna
CI
$72.7B
$10.3M 1.31%
55,000
+10,000
+22% +$1.78M
BMY icon
28
Bristol-Myers Squibb
BMY
$131B
$10.2M 1.31%
160,502
+46,907
+41% +$2.74M
HUM icon
29
Humana
HUM
$44.1B
$9.99M 1.28%
41,000
+6,000
+17% +$1.47M
AET
30
DELISTED
Aetna Inc
AET
$9.86M 1.26%
62,000
+25,000
+68% +$3.91M
REGN icon
31
Regeneron Pharmaceuticals
REGN
$79.5B
$9.84M 1.26%
22,000
+6,900
+46% +$3.28M
CVS icon
32
CVS Health
CVS
$123B
$9.76M 1.25%
120,000
+35,000
+41% +$2.77M
LLY icon
33
Eli Lilly
LLY
$1.06T
$9.41M 1.2%
110,000
-40,000
-27% -$3.28M
EW icon
34
Edwards Lifesciences
EW
$51.5B
$8.74M 1.12%
240,000
+141,000
+142% +$5.38M
ABT icon
35
Abbott
ABT
$187B
$8.27M 1.06%
155,000
+60,000
+63% +$3.01M
BSX icon
36
Boston Scientific
BSX
$71.4B
$8.18M 1.04%
+280,468
New +$7.75M
DVAX
37
DELISTED
Dynavax Technologies
DVAX
$8.05M 1.03%
374,537
-212,793
-36% -$3.37M
ARRY
38
DELISTED
Array Biopharma Inc
ARRY
$8M 1.02%
650,000
+225,000
+53% +$2.09M
KYNB
39
Kyntra Bio
KYNB
$28.3M
$7.83M 1%
5,820
-354
-6% -$373K
ALKS icon
40
Alkermes
ALKS
$8.11B
$7.37M 0.94%
145,000
+9,591
+7% +$513K
NBIX icon
41
Neurocrine Biosciences
NBIX
$16.2B
$7.05M 0.9%
115,000
-5,000
-4% -$264K
IMMU
42
DELISTED
Immunomedics Inc
IMMU
$6.99M 0.89%
500,000
-29,610
-6% -$295K
LOXO
43
DELISTED
Loxo Oncology, Inc
LOXO
$6.91M 0.88%
+75,000
New +$5.83M
BIIB icon
44
Biogen
BIIB
$30.5B
$6.89M 0.88%
22,000
-26,500
-55% -$7.85M
RVNC
45
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.79M 0.87%
246,400
+26,400
+12% +$640K
ELGX
46
DELISTED
Endologix Inc
ELGX
$6.66M 0.85%
149,260
-8,240
-5% -$375K
LIVN icon
47
LivaNova
LIVN
$4.17B
$6.66M 0.85%
95,000
-6,854
-7% -$434K
COR icon
48
Cencora
COR
$62B
$6.62M 0.85%
80,000
+35,000
+78% +$2.97M
SNY icon
49
Sanofi
SNY
$103B
$6.47M 0.83%
130,000
-30,000
-19% -$1.45M
MYOK
50
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$6.46M 0.83%
+150,872
New +$4.81M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
OC
Oarsman Capital Milwaukee, Wisconsin $806M AUM 19.96% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rhenman & Partners Asset Management held 120 positions worth $783M, up 12% from $696M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $43.3M of net new capital in Q3 2017, opening 12 new positions and adding to 45 existing holdings. Its largest new stake was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Pfizer, an estimated $14.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2017 buy was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.
  • Rhenman & Partners Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $12.8M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2017 reduction was Pfizer, cutting an estimated $14.2M.
  • Rhenman & Partners Asset Management fully exited NeuroDerm Ltd. Ordinary Shares in Q3 2017, selling an estimated $13.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $783M portfolio in Q3 2017.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 26 in Q3 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $783M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.